Ken Griffin An2 Therapeutics, Inc. Call Options Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANTX
# of Institutions
33Shares Held
13.5MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$7.24 Million3.62% of portfolio
-
Ra Capital Management, L.P. Boston, MA2MShares$2.52 Million0.03% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.96 Million0.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.31 Million0.0% of portfolio
-
Acuitas Investments, LLC446KShares$561,6860.23% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $24.4M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...